A startup from UCF’s School of Medicine applying exosome technology to regenerative medicine, drug delivery, non-invasive diagnostics, and medical device development. It aims to improve quality of life through innovative healthcare solutions for intractable diseases.
アカデミアにて研究開発された医療技術の展開を行うアメリカ・セントラルフロリダ大学医学部発ベンチャー(株)プロジェニサイトジャパン（本社：神戸市、代表取締役CEO：徐綾）は、この度COVID-19 診断の為のネ...
弊社はセントラルフロリダ大学医学部教授・同大学脳神経科学研究所所長の菅谷公伸博士が研 究開発を行った化合物及び最先端の医療技術（国際特許数・２８、申請中を含めると６０以上）の 市場展開を行ってゆき...
We provide contract analysis services utilizing mass spectrometry imaging. This technology enables visualization of “where, what components, and how much.” It is applicable to pharmacokinetic studies, cosmetic development, and various other fields.
A Deep Tech company combining AI with behavioral science to visualize and optimize human and organizational behavior. It supports sustainable behavior change that balances growth and well-being.
Utilizing the unique genome editing technology CRISPR-Cas3, C4U develops industrial applications to combat diseases that currently have no effective treatments.
We develop and sell therapeutic drugs and skin care cosmetics, focusing on drug transdermal absorption technology that can absorb both water-soluble and hydrophobic compounds of large molecular weight. In particular, in joint research with Kobe University, we found that carbon dioxide transdermal absorption has an increase and activation effect on mitochondria, and it has been revealed that it can safely increase muscle strength, promote healing of wounds/fractures, and inhibit scarring, partial weight loss by promoting fat metabolism, and induce apoptosis in cancer cells. Some products are on the market not only in Japan but also in other countries.
